Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388

FORMA Therapeutics Receives FDA Orphan Drug Designation For FT-4202 For The Treatment Of Sickle Cell Disease

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation And Rare Pediatric Disease Designation For Treatment Of Sickle Cell Disease

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis

FORMA Reports Achievement Of Early-Stage Clinical Development Milestones For Assets Licensed Exclusively To Boehringer Ingelheim And Bristol-Myers Squibb

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

FORMA Therapeutics Announces Closing Of $100 Million Series D Financing

Enrollment complete in Third Phase 3 Clinical Trial for VT-1161 (ultraVIOLET) in Patients with Recurrent Vulvovaginal Candidiasis

FORMA Therapeutics Announces Positive Preliminary Phase 1/2 IDH1m Inhibitor Olutasidenib Results Demonstrating Rapid Clinical Remissions And Mutation Clearance In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndrome

FORMA Therapeutics Announces Clinical Data For Sickle Cell Disease Candidate FT-4202, Demonstrating Multi-Modal Activity Of PKR Activation Increases Oxygen Affinity And Decreases Sickle Hemoglobin Polymerization, At 61st Annual ASH

Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia

FORMA Therapeutics’ Olutasidenib Demonstrates Positive Phase 1b/2 Results, Including Blood-Brain Barrier Penetration And Stable Disease In Patients With IDH1-Mutated Glioma

Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day

Enrollment completed early for Global Phase 3 Clinical Trials for VT-1161 (VIOLET) for the Treatment of Recurrent Vulvovaginal Candidiasis

FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis In Healthy Adult Subjects

Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn’s Disease

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

FORMA Therapeutics Announces New Executive Leadership To Execute Next Phase Of Growth For Company

Kymera Therapeutics is Named one of FierceBiotech’s “Fierce 15” Companies of 2019

Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team

FORMA Therapeutics Announces Data For IDH1m Inhibitor Olutasidenib In Glioma To Be Presented At The 2019 Society For NeuroOncology Annual Meeting

Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium